Cooley-Led Adagio Plots Course For $301M IPO
Adagio, a life sciences company focused on developing an antibody-based treatment for COVID-19 and other coronaviruses, laid out terms Monday for a $301 million initial public offering guided by Cooley LLP...To view the full article, register now.
Already a subscriber? Click here to view full article